Shopping Cart 0
Cart Subtotal
USD 0

Acadia Pharmaceuticals Inc (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. The company's lead product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson's disease psychosis. Acadia also develops pimavanserin for the treatment of Alzheimer's disease agitation and Alzheimer's disease psychosis and as an adjunctive treatment for schizophrenia and major depressive disorder (MDD). The company has partnerships for the development of its drug candidates in the therapeutic areas of pain and ophthalmology. It has operational presence in Denmark and Switzerland. Acadia is headquartered in San Diego, California, the US.

Acadia Pharmaceuticals Inc (ACAD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

ACADIA Pharma Enters into Licensing Agreement with Neuren Pharma 10

Equity Offering 11

Acadia Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD230 Million 11

Acadia Pharma Raises USD300 Million in Public Offering of Shares 13

Acadia Pharma Raises USD209.8 Million in Public Offering of Shares 15

Acadia Pharma Completes Public Offering Of Shares For USD 115 Million 17

Acadia Pharma Completes Private Placement Of Shares And Warrants For USD 84 Million 19

Acadia Pharmaceuticals Inc-Key Competitors 20

Acadia Pharmaceuticals Inc-Key Employees 21

Acadia Pharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 07, 2018: ACADIA Pharmaceuticals reports third quarter 2018 financial results 23

Aug 08, 2018: ACADIA Pharmaceuticals reports second quarter 2018 financial results 25

May 04, 2018: ACADIA Pharmaceuticals Announces First Quarter 2018 Financial Results 27

Feb 27, 2018: ACADIA Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 29

Nov 07, 2017: ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results 31

Aug 08, 2017: ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results 33

May 09, 2017: ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results 35

Feb 28, 2017: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 37

Corporate Communications 39

Sep 26, 2018: ACADIA Pharmaceuticals announces executive appointments 39

May 02, 2018: ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations 40

Dec 13, 2017: ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development 41

Mar 30, 2017: ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer 42

Legal and Regulatory 43

Jul 25, 2018: Federman & Sherwood announces filing of securities class action lawsuit against Acadia Pharmaceuticals 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acadia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ACADIA Pharma Enters into Licensing Agreement with Neuren Pharma 10

Acadia Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD230 Million 11

Acadia Pharma Raises USD300 Million in Public Offering of Shares 13

Acadia Pharma Raises USD209.8 Million in Public Offering of Shares 15

Acadia Pharma Completes Public Offering Of Shares For USD 115 Million 17

Acadia Pharma Completes Private Placement Of Shares And Warrants For USD 84 Million 19

Acadia Pharmaceuticals Inc, Key Competitors 20

Acadia Pharmaceuticals Inc, Key Employees 21

Acadia Pharmaceuticals Inc, Other Locations 22

Acadia Pharmaceuticals Inc, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Acadia Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. The company's lead product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson's disease psychosis. Acadia also develops pimavanserin for the treatment of Alzheimer's disease agitation and Alzheimer's disease psychosis and as an adjunctive treatment for schizophrenia and major depressive disorder (MDD). The company has partnerships for the development of its drug candidates in the therapeutic areas of pain and ophthalmology. It has operational presence in Denmark and Switzerland. Acadia is headquartered in San Diego, California, the US.

Acadia Pharmaceuticals Inc (ACAD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

ACADIA Pharma Enters into Licensing Agreement with Neuren Pharma 10

Equity Offering 11

Acadia Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD230 Million 11

Acadia Pharma Raises USD300 Million in Public Offering of Shares 13

Acadia Pharma Raises USD209.8 Million in Public Offering of Shares 15

Acadia Pharma Completes Public Offering Of Shares For USD 115 Million 17

Acadia Pharma Completes Private Placement Of Shares And Warrants For USD 84 Million 19

Acadia Pharmaceuticals Inc-Key Competitors 20

Acadia Pharmaceuticals Inc-Key Employees 21

Acadia Pharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 07, 2018: ACADIA Pharmaceuticals reports third quarter 2018 financial results 23

Aug 08, 2018: ACADIA Pharmaceuticals reports second quarter 2018 financial results 25

May 04, 2018: ACADIA Pharmaceuticals Announces First Quarter 2018 Financial Results 27

Feb 27, 2018: ACADIA Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 29

Nov 07, 2017: ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results 31

Aug 08, 2017: ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results 33

May 09, 2017: ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results 35

Feb 28, 2017: ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 37

Corporate Communications 39

Sep 26, 2018: ACADIA Pharmaceuticals announces executive appointments 39

May 02, 2018: ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations 40

Dec 13, 2017: ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development 41

Mar 30, 2017: ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer 42

Legal and Regulatory 43

Jul 25, 2018: Federman & Sherwood announces filing of securities class action lawsuit against Acadia Pharmaceuticals 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44


List Of Figure

List of Figures

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acadia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Acadia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ACADIA Pharma Enters into Licensing Agreement with Neuren Pharma 10

Acadia Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering for USD230 Million 11

Acadia Pharma Raises USD300 Million in Public Offering of Shares 13

Acadia Pharma Raises USD209.8 Million in Public Offering of Shares 15

Acadia Pharma Completes Public Offering Of Shares For USD 115 Million 17

Acadia Pharma Completes Private Placement Of Shares And Warrants For USD 84 Million 19

Acadia Pharmaceuticals Inc, Key Competitors 20

Acadia Pharmaceuticals Inc, Key Employees 21

Acadia Pharmaceuticals Inc, Other Locations 22

Acadia Pharmaceuticals Inc, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Acadia Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.